In what ways could the emergence of a cancer‑derived therapy for multiple sclerosis reshape pharmaceutical R&D investment models and regulatory pathways?
The emergence of cancer-derived therapies for multiple sclerosis represents one of the most consequential developments in pharmaceutical innovation, fundamentally altering how companies conceptualize R&D investments, navigate regulatory frameworks, and construct therapeutic portfolios. This paradigm shift—exemplified by the successful translation of anti-CD20 antibodies, CD52-targeting agents, and purine antimetabolites from oncology to neurology—has created a new template for drug development that promises accelerated timelines, reduced costs, and novel pathways to market exclusivity.
The foundation for understanding how cancer-derived MS therapies reshape investment models lies in examining the documented transitions that have already occurred. Rituximab, a chimeric mouse-human monoclonal antibody approved in 1997 for B-cell lymphoma, became one of the first monoclonal antibodies developed for clinical use and has since been used in more than 184,000 patients with rheumatoid arthritis, in addition to widespread off-label use in MS B Cell Therapy for Multiple Sclerosis: Entering an Era - PMC nih . The 2008 phase II trial demonstrating rituximab's remarkable reduction in inflammatory brain lesions and clinical relapses in relapsing-remitting MS was "somewhat of a surprise given what we know or thought we knew about disease pathogenesis"The Role of B Cells in Progressive MS and the Long term Effects of B Cell Depletionyoutube .
This success catalyzed the development of ocrelizumab, a humanized anti-CD20 antibody designed specifically for MS, which gained FDA approval in 2017 for both relapsing and primary progressive forms of MS B Cell Therapy for Multiple Sclerosis: Entering an Era - PMC nih . Ocrelizumab exhibits greater antibody-dependent cellular cytotoxicity compared to rituximab and depletes B cells through multiple mechanisms including apoptosis and antibody-dependent cellular phagocytosis B Cell Therapy for Multiple Sclerosis: Entering an Era - PMC nih . The OPERA 1 and OPERA 2 trials demonstrated 46% and 47% reductions in annualized relapse rate compared to interferon beta-1a, while the ORATORIO trial in primary progressive MS showed the first effective disease-modifying therapy for this previously untreatable condition B Cell Therapy for Multiple Sclerosis: Entering an Era - PMC nih .
Alemtuzumab provides perhaps the most instructive case study of regulatory navigation. Originally developed by Herman Waldmann as a laboratory tool to investigate immune tolerance, it became the first humanized monoclonal antibody drug and was initially approved for B-cell chronic lymphocytic leukemia by the FDA and EMA in 2001 Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use - PMC nih . The first MS patient was treated with the drug in 1991, and subsequent trials demonstrated efficacy in relapsing-remitting MSThe life story of a biotechnology drug Alemtuzumab: Timelinewhatisbiotechnology . The European Commission approved alemtuzumab (Lemtrada) for MS treatment in September 2013, but the FDA initially denied approval owing to concerns about study design—specifically that patients were not blinded to treatment assignment Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use - PMC nih . After resubmission with additional data analyses, FDA approval came in November 2014, generally reserved for patients who have had an inadequate response to two or more MS drugs Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use - PMC nih .
Cladribine's trajectory further illustrates the regulatory complexities. This purine antimetabolite was approved for hairy cell leukemia and chronic lymphocytic leukemia before being repurposed for MSMavenclad (Cladribine) for Multiple Sclerosis Explained by Neurologistyoutube . The CLARITY trial demonstrated a 58% reduction in relapse rate and 33% reduction in disability progression compared to placeboMultiple Sclerosis Vlog: MAVENCLAD (Cladribine) for MSyoutube . Notably, the drug "didn't get FDA approved" initially, and clinical trials were completed before 2008—the first FDA submission received a Refusal to File letter, and following a Complete Response Letter in 2010, the company stated it was "no longer going to pursue global approval"Multiple Sclerosis Vlog: MAVENCLAD (Cladribine) for MSyoutube +1. European approval finally came in 2017, followed by FDA approval in 2019—more than a decade after the pivotal trialsFDA Approves Cladribine (Brand-named Mavenclad®) - Rocky Mountain MS Centermscenter .
The success of cancer-derived MS therapies has fundamentally reshaped regulatory frameworks, creating new precedents for expedited development of repurposed drugs. The FDA's 505(b)(2) New Drug Application pathway offers a strategic opportunity for sponsors to streamline development plans, accelerate approval timelines, and potentially reduce clinical costs by allowing reliance on the FDA's previous findings of safety and effectiveness for previously approved drugs505(b)(2) Pathway CRO | Premier Researchpremier-research . This pathway is exceptionally well-suited for repurposed drugs because sponsors can avoid conducting duplicative preclinical and early-phase clinical safety studies—the most time-consuming and expensive components of drug developmentPatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch .
The 505(b)(2) pathway functions as "the commercial engine of drug repurposing"—without the ability to rely on existing data, the economic model for most repurposing projects would collapsePatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch . The cost to develop a drug de novo can exceed $1 billion, an investment impossible to justify for an off-patent compound facing immediate generic competitionPatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch .
Breakthrough Therapy designation has become increasingly relevant for MS therapies. In December 2017, the FDA granted Breakthrough Therapy designation for fingolimod for pediatric MS based on the PARADIGMS study, which demonstrated an 82% reduction in annualized relapse rate compared to interferon beta-1aNovartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS | Novartis United States of Americanovartis . More recently, in December 2024, tolebrutinib received Breakthrough Therapy designation for non-relapsing secondary progressive MS based on the HERCULES trial showing a 31% reduction in confirmed disability progression compared to placeboPress Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosissanofi .
The European Medicines Agency's PRIME (PRIority MEdicines) scheme, launched in 2016, provides enhanced support for medicines addressing unmet medical needsEMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Applyprecisionformedicine . Recent analysis demonstrated that for advanced therapy medicinal products, PRIME designation reduced time from marketing authorization procedure start to European Commission approval by 42.7%—approximately one year reduction (median of 376 days for PRIME versus 669 days for non-PRIME products)EMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Applyprecisionformedicine . This acceleration results from fewer clock stops (2 versus 3) and shorter clock stops (99 days versus 358 days) compared to non-PRIME productsEMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Applyprecisionformedicine .
The proposed EU pharmaceutical package includes Article 48, which would allow non-profit entities to submit clinical evidence for new therapeutic indications to the EMA for consideration—effectively allowing third parties to pursue label extensions when marketing authorization holders decline to do soDrug repurposing: EU legislative changes could speed up new treatment options | Cancerworld Magazinecancerworld . Article 84 offers 4 years of data exclusivity for repurposed medicines that have not previously benefited from regulatory exclusivity or for which 25 years have passed since marketing authorization Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions - PMC nih .
The economic case for cancer-derived MS therapies fundamentally alters pharmaceutical investment calculations. Traditional de novo drug discovery typically requires 10-17 years and investments exceeding $2 billion with only 11% of Phase I candidates reaching approval Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review - PMC nih . Drug repurposing reduces development timelines to 3-12 years at substantially lower costs, with approval rates reaching approximately 30% for de-risked compounds Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review - PMC nih . A repositioning campaign, from initial identification to market introduction, averages six and a half years and requires more than $200 million—compared to 13-15 years and $2-3 billion for new chemical entities Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review - PMC nih .
The current cost of bringing a new cancer drug to market is estimated at $2-4.5 billion including all failures along the way, with approximately 90% of costs attributed to clinical trials rather than high-tech lab workhow can we overcome the drug repurposing paradox?cancerworld . Phase II trials typically cost £20-30 million (€23-35 million), and Phase III trials £50-70 million (€58-81 million)how can we overcome the drug repurposing paradox?cancerworld . For repurposed drugs with established safety profiles, much of the preclinical testing, safety assessment, and in some cases even Phase I clinical trials can be leveraged for the new indicationDrug repurposing: EU legislative changes could speed up new treatment options | Cancerworld Magazinecancerworld .
The global drug repurposing market was valued at over $35 billion in 2024, with projections for substantial growth—an estimated $8.57 billion increase from 2024-2028, representing a 4.3% compound annual growth ratePatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch +1. Repurposed drugs already contribute an estimated 25% to 40% of annual pharmaceutical revenuePatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch .
Venture capital has responded aggressively to this opportunity. In the first half of 2024, venture capitalists pledged more than $1.7 billion to companies developing treatments for autoimmune conditions, and if this trend continues, autoimmune companies could raise double the amount raised at the height of the biotech market in 2021Chasing CAR-T, biotech finds its next gold rush in autoimmune disease - STAT Newsstatnews . The first half of 2025 saw robust activity with autoimmune-focused ventures securing $1.1 billion across 17 financings, matching the volume and value seen in the second half of 2024Autoimmune R&D Partnerships, M&A and Venture Funding – H1 2025 Review - DealFormadealforma .
Notable recent fundings include Abcuro raising $200 million in February 2025 to advance its Phase 2/3 program for inclusion body myositis, Timberlyne Therapeutics securing $180 million in January 2025 for a CD38-targeting antibody for autoimmune diseases, and GlycoEra closing a $130 million Series B in May 2025 for its IgG4-targeted degraderAutoimmune R&D Partnerships, M&A and Venture Funding – H1 2025 Review - DealFormadealforma . Denali Therapeutics raised $600 million in a 2024 PIPE—the largest biotech PIPE of the year—to fund its neurodegenerative disease pipeline Biotechnology Market Funding Trends (2022 - 2026) – New Market Pitchnewmarketpitch .
Bruton's tyrosine kinase (BTK) inhibitors represent the current frontier of cancer-to-MS translation and provide instructive lessons about investment risk. BTK is expressed by both B cells and myeloid cells including microglia within the CNS, making brain-penetrant BTK inhibitors potentially capable of targeting chronic compartmentalized CNS inflammation in progressive MS that has evaded treatment to date MS Minute: Update on BTK Inhibitors for Multiple Sclerosis - practicalneurology .
At least four BTK inhibitors are in late clinical development for MS: tolebrutinib (Sanofi), evobrutinib (Merck), fenebrutinib (Genentech), and remibrutinib (Novartis)Updates on BTK inhibitor safety in multiple sclerosisyoutube . However, the results have been mixed, demonstrating both the promise and peril of this approach.
Evobrutinib failed in two Phase III trials (EvolutionRMS 1 and 2) with 2,290 participants—neither trial showed a difference in relapse rate compared to teriflunomide (adjusted rate ratio 1.02 for EvolutionRMS1 and 1.00 for EvolutionRMS2) MS Minute: Update on BTK Inhibitors for Multiple Sclerosis - practicalneurology . Tolebrutinib similarly failed in relapsing MS (GEMINI 1 and 2 trials with 1,873 participants), but succeeded in non-relapsing secondary progressive MS (HERCULES trial), demonstrating a 31% reduction in 6-month confirmed disability worsening MS Minute: Update on BTK Inhibitors for Multiple Sclerosis - practicalneurology .
The PERSEUS trial results announced in December 2025 showed tolebrutinib did not meet its primary endpoint in primary progressive MS, and Sanofi will not pursue regulatory registration for this indicationPress Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosissanofi . Most critically, in December 2024 the FDA declined to approve tolebrutinib, citing concerns about liver safety—specifically that "we were unable to identify a population for which the benefit could be clearly established and for which that benefit would be anticipated to outweigh the serious risk of severe DILI"Tolebrutinib and Fenebrutinib: An Update for the MS Communitymscenter .
Drug-induced liver injury has emerged as a class-wide concern for BTK inhibitors. Hepatic signals were reported with both tolebrutinib and fenebrutinibUpdates on BTK inhibitor safety in multiple sclerosisyoutube . Tolebrutinib development in the United States was placed on clinical hold, meaning recruiting trials could no longer enroll new participantsUpdates on BTK inhibitor safety in multiple sclerosisyoutube . This illustrates how cancer-derived therapies can carry unexpected safety signals when applied to chronic neurological conditions requiring long-term treatment.
Novartis's remibrutinib is advancing through the Phase III REMODEL-2 study (NCT05156281), expected to complete by April 2026 with 800 enrolled patientsMultiple sclerosis: three trials to watch - Clinical Trials Arenaclinicaltrialsarena . Fenebrutinib remains on track in development, with study results anticipated at ACTRIMS and AAN conferencesTolebrutinib and Fenebrutinib: An Update for the MS Communitymscenter .
The pricing differential between cancer-derived MS therapies and their oncology-origin counterparts creates significant market access considerations that reshape investment calculations. From 2018 to 2021, the annual price of ocrelizumab was more than 4 times higher than rituximab in Medicare ($69,949 versus $11,759 in Q4 2021) and 8 times higher in Medicaid ($47,671 versus $5,893) Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis - PMC nih .
This pricing disparity has substantial fiscal implications. From 2018 to 2021, ocrelizumab spending totaled $2.5 billion in Medicare and $670 million in Medicaid. Had ocrelizumab's net price been consistent with rituximab, savings would have been $1.9 billion (76%) for Medicare and $590 million (86%) for Medicaid Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis - PMC nih .
The Institute for Clinical and Economic Review's 2024 assessment found that current evidence is not adequate to distinguish net health benefit between monoclonal antibodies for MS (ocrelizumab, natalizumab, ofatumumab, ublituximab, rituximab)ICER Publishes Final Evidence Report on Treatments for Multiple Sclerosis - ICERicer . ICER's analysis determined these monoclonal antibodies would achieve common cost-effectiveness thresholds if priced between $16,500-$34,900 per year—"a range far lower than current market prices net of all rebates"ICER Publishes Final Evidence Report on Treatments for Multiple Sclerosis - ICERicer .
The base-case model outcomes demonstrated lifetime treatment costs of $997,000-$1,893,000 for monoclonal antibodies, with incremental cost-effectiveness ratios versus dimethyl fumarate ranging from $292,000 per QALY for ocrelizumab to $760,000 per QALY for natalizumab[PDF] Oral and Monoclonal Antibody Treatments for Relapsing Forms of ...icer . Notably, ocrelizumab demonstrated the most favorable cost-effectiveness profile among monoclonal antibodies at $186,000 per additional year without ambulatory restrictions and $223,000 per additional year without wheelchair use[PDF] Oral and Monoclonal Antibody Treatments for Relapsing Forms of ...icer .
Rituximab's off-label use in MS has created a unique regulatory precedent. Medicare's Local Coverage Determination explicitly includes Multiple Sclerosis (ICD-10 code G35) as a covered off-label indication, requiring documentation of previous treatments and response to therapyArticle - Billing and Coding: Off-label Use of Rituximab and ... - CMScms . The Swedish MS registry followed 6,421 patients including 3,260 on rituximab over six years, finding approximately doubled risk of serious infections with rituximab compared with other disease-modifying therapies (22.7 versus 10.4-11.4 events per 1,000 person-years) Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study - PMC nih .
Biosimilar competition is reshaping this landscape. In Britain, biosimilar forms of rituximab from Celltrion and Novartis have captured 80% of the market since launching, with discounts of 50-60% saving the NHS £80 million annuallyWednesday, March 28, 2018khn . The critical question for pharmaceutical investment is whether payers will allow off-label extrapolation of biosimilars—a determination that could fundamentally alter market dynamicsAli McBride, PharmD, MS, BCPS: Preparing for Biosimilar Rituximabyoutube .
Cancer-derived MS therapies require sophisticated intellectual property strategies that differ markedly from traditional drug development. Since the active pharmaceutical ingredient is often off-patent or in the public domain, innovators must seek protection for new applications through Method of Treatment patents claiming "A method of treating [disease], comprising administering a therapeutically effective amount of [drug]"Patenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch .
The creation of "patent thickets"—dense, overlapping webs of various patent types—has become standard practicePatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch . These multi-layered defenses include:
These secondary patents work synergistically to overcome enforcement weaknesses of standalone method-of-use patents, which are vulnerable to off-label prescribing where generic companies launch products with "skinny labels" for unpatented usesPatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch .
Key exclusivity mechanisms under the 505(b)(2) pathway include:
Type | Duration | Trigger | |
|---|---|---|---|
| New Clinical Investigation | 3 years | New indication requiring new clinical studies | |
| Orphan Drug | 7 years | Drug for disease affecting <200,000 patients | |
| New Chemical Entity | 5 years | Less common for repurposed drugs | |
| Pediatric | 6 months | Added to existing exclusivities |
Frequently Asked Questions on Patents and Exclusivity - FDAfda
Critically, enforcement remains challenging: once original patents expire and generics become available, the generic version is "often prescribed for all indications for which the brand name drug is approved regardless of market exclusivity"Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort studyplos +1. Analysis found that 92.5% of extensions for new indications were authorized during the exclusivity period of the original productDiminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort studyplos +1.
The cancer-to-MS translation model is catalyzing fundamental changes in how pharmaceutical companies construct therapeutic portfolios. Companies are increasingly designing development programs that simultaneously pursue oncology and autoimmune/neurological indications from the outset.
I-Mab exemplifies this dual-indication strategy, focusing on both immuno-oncology and autoimmune diseasesI-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021prnewswire . Their felzartamab (CD38 antibody) is being developed for both relapsed/refractory multiple myeloma and autoantibody-mediated autoimmune diseases including systemic lupus erythematosusI-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021prnewswire . This approach recognizes that "the same mechanism or the same target can indeed be applied to both oncology and autoimmune disease but generally the assets are distinct, tailored to the therapeutic context"Autoimmunity and Oncology: New Targets in Immunology | Yale Innovation Summit 2025youtube .
The licensing deal landscape reflects this convergence. Novartis's 2024 deal with PTC Therapeutics paid $1 billion upfront plus up to $1.9 billion in milestones for PTC518 in Huntington's disease—a brain-penetrant small molecule designed to cross the blood-brain barrierThe Top 7 Biopharma Licensing Deals of 2024 - BioSpacebiospace . Bristol Myers Squibb invested $3.61 billion in Prime Medicine's gene editing cell therapy partnership for immunology and oncology targetsThe Top 7 Biopharma Licensing Deals of 2024 - BioSpacebiospace . Vor Bio's June 2025 deal with RemeGen for telitacicept—a dual BLyS/APRIL inhibitor approved in China for myasthenia gravis, lupus, and rheumatoid arthritis—was valued at potentially more than $4 billionEight of the biggest immunology and inflammation (I&I) deals in 2025labiotech .
T-cell engagers represent an emerging crossover category. Recent research published in the New England Journal of Medicine demonstrated that teclistamab, a BCMA T-cell engager originally developed for oncology, produced B-cell depletion lasting a median of five months with sharp autoantibody reductions in patients with refractory autoimmune diseases including systemic sclerosis and Sjögren's syndrome—with six of ten patients achieving drug-free remission lasting up to fifteen monthsBiopharma Outlook - November 24, 2025stifel .
The integration of real-world evidence into regulatory decision-making is particularly relevant for cancer-derived MS therapies, which benefit from extensive post-marketing safety databases in their oncology indications. The FDA's Real-World Evidence Program, established under the 21st Century Cures Act, provides a framework for using RWE to support approval of new indications for already-approved drugs or to satisfy post-approval study requirementsReal-World Evidence - FDAfda .
The December 2025 FDA guidance on real-world evidence for medical devices clarified how the agency evaluates real-world data for regulatory decision-making, emphasizing that RWE can offer advantages over traditional clinical trials by capturing broader clinical experiences and reducing time and cost burdens Federal Register :: Use of Real-World Evidence To Support Regulatory Decision-Making for Medical Devices; Guidance for Industry and Food and Drug Administration Staff; Availability federalregister . This framework is being extended to drug applications, with particular relevance for repurposed drugs with established safety profiles.
Systematic review of FDA approvals for rare diseases found that 95% of applications using real-world data employed only retrospective studies, with the FDA generally accepting RWD studies demonstrating large effect sizes despite noted concerns about quality and comparabilityA systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.nih . This creates opportunities for cancer-derived MS therapies to leverage existing oncology datasets in supporting new neurological indications.
The emergence of cancer-derived MS therapies is reshaping pharmaceutical investment models across multiple dimensions:
Risk Reduction: The ability to leverage existing safety data reduces clinical development risk from approximately 90% failure rate for novel compounds to approximately 70% for repurposed drugsDrug repurposing: Applying yesterday's solutions to tomorrow’s problems | Bessi Qorri | TEDxQueensUyoutube . The mean interval between first approval and repurposing is 7.2 years—shorter than typical development timelines for newly originated drugs Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation - PMC nih .
Capital Efficiency: Development costs can be reduced by 50-60% compared to de novo drug discoveryPatenting New Uses for Existing Drugs: A Legal and Strategic Analysis of Drug Repurposing - DrugPatentWatch – Transform Data into Market Dominationdrugpatentwatch . Repurposed drugs gain approval in 3-7 years at less than 60% of the cost of new drugs entering the marketDrug repurposing: Applying yesterday's solutions to tomorrow’s problems | Bessi Qorri | TEDxQueensUyoutube .
Portfolio Diversification: Companies can pursue dual-indication strategies that hedge oncology and autoimmune risks while maximizing returns on R&D investments in shared mechanisms like B-cell depletion, BTK inhibition, and CD38 targeting.
Regulatory Pathway Innovation: Expedited designations (Breakthrough Therapy, PRIME, Fast Track) create competitive advantages for first movers in cancer-to-autoimmune transitions.
Pricing Complexity: The tension between innovator pricing for novel indications and generic/biosimilar competition in original indications creates challenging market access dynamics requiring sophisticated pricing strategies.
The financing environment supports continued expansion of this model. Total biopharma financing in 2025 is approaching pandemic-level records, potentially becoming the fourth most active financing year on recordBiopharma Outlook - November 24, 2025stifel . Autoimmune and immunology ventures have raised approximately $7.1 billion through 70+ deals during the recent period Biotechnology Market Funding Trends (2022 - 2026) – New Market Pitchnewmarketpitch .
The paradigm established by cancer-derived MS therapies—exemplified by the anti-CD20 antibodies, alemtuzumab, cladribine, and now BTK inhibitors—has created a reproducible template for pharmaceutical innovation that promises to accelerate therapeutic development across neurological and autoimmune diseases while fundamentally altering how companies, investors, and regulators approach drug development. The lessons learned from both successes and failures in this space will continue to reshape investment models, regulatory frameworks, and portfolio strategies for the foreseeable future.